Clinical Trial

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation and inhalation suspension administered in a single dose in healthy individuals and multiple doses in patients with COPD
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-04; most recent amendment 2026-02-24.
Status change: Not Yet Recruiting → Recruiting 2025-09-01
Trial Details
NCT Number NCT07116915
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions COPD
Enrollment 160 participants
Start Date 2025-08-11
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-27